The RTEL1 rs6010620 Polymorphism and Glioma Risk: a Meta-analysis Based on 12 Case-control Studies

Background: The association between the RTEL1 rs6010620 single nucleotide polymorphism (SNP) and gliomarisk has been extensively studied. However, the results remain inconclusive. To further examine this association,we performed a meta-analysis. Materials and
Methods: A computerized search of the PubMed and Embasedatabases for publications regarding the RTEL1 rs6010620 polymorphism and glioma cancer risk was performed.Genotype data were analyzed in a meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) wereestimated to assess the association. Sensitivity analyses, tests of heterogeneity, cumulative meta-analyses, andassessments of bias were performed in our meta-analysis.
Results: Our meta-analysis confirmed that risk withallele A is lower than with allele G for glioma. The A allele of rs6010620 in RTEL1 decreased the risk of developingglioma in the 12 case-control studies for all genetic models: the allele model (OR=0.752, 95%CI: 0.715-0.792),the dominant model (OR=0.729, 95%CI: 0.685-0.776), the recessive model (OR=0.647, 95%CI: 0.569-0.734), thehomozygote comparison (OR=0.528, 95%CI: 0.456-0.612), and the heterozygote comparison (OR=0.761, 95%CI:0.713-0.812).
Conclusions: In all genetic models, the association between the RTEL1 rs6010620 polymorphismand glioma risk was significant. This meta-analysis suggests that the RTEL1 rs6010620 polymorphism may be arisk factor for glioma. Further functional studies evaluating this polymorphism and glioma risk are warranted.